Phaseline

Companies › Anterogen

Anterogen: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASC (Autologous Adipose-derived Mesenchymal Stem Cells)
Autologous adipose-derived mesenchymal stem cells
–Phase 3Crohn's Fistula–
ANT-301
Unclear - biological therapy for knee osteoarthritis
–Phase 1Osteoarthritis, Knee–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04612465ASC (Autologous Adipose-derived Mesenchymal Stem Cells)Phase 3Crohn's FistulaImmunologyApr 2025
NCT06539429ANT-301Phase 1Osteoarthritis, KneeImmunologyMay 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ALK-Abelló Aravax VivaTech International AltruBio Qu Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.